Compare AbCellera Biologics Inc (ABCL) vs HP Inc (HPQ) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

HPQ trades at $22.96, up 4.7% today, with strong earnings momentum as it has beaten EPS estimates for three consecutive quarters. The stock shows attractive valuation metrics with a P/E of 8.37 and P/S of 0.37, while technical indicators signal bearish momentum despite oversold RSI conditions. Recent developments include strategic AI partnerships with OpenAI and Ferrari, positioning the company for potential growth in the AI PC market.

The outlook remains cautiously optimistic with analyst consensus at $22.00, slightly below current price. Key opportunities include AI PC adoption and margin expansion, while risks involve competitive pressures and declining profit margins. Institutional sentiment leans neutral with 55% hold ratings, suggesting balanced risk-reward for value-oriented investors.